Zimmer Holdings (NY:ZBH)

90.45 +2.16 (+2.45%)

Delayed Quote Updated: 10:49 AM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Zimmer Holdings

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

ZBH Q4 Deep Dive: U.S. Salesforce Overhaul Drives Guidance Caution Amid Product Momentum

February 11, 2026

Medical device company Zimmer Biomet (NYSE:ZBH) reported Q4 CY2025 results topping the market’s revenue expectations, with sales up 10.9% year on year to $2.24 billion. Its non-GAAP profit of $2.42 per...

Via StockStory

Zimmer Biomet (ZBH) Q4 2025 Earnings Transcript ↗

February 10, 2026

Zimmer Biomet (ZBH) Q4 2025 Earnings Transcript

Via The Motley Fool

Zimmer Biomet (NYSE:ZBH) Beats Q4 CY2025 Sales Expectations

February 10, 2026

Via StockStory

Topics World Trade

What To Expect From Zimmer Biomet’s (ZBH) Q4 Earnings

February 08, 2026

Medical device company Zimmer Biomet (NYSE:ZBH) will be announcing earnings results this Tuesday before market open. Here’s what investors should know.

Via StockStory

Topics Artificial Intelligence World Trade

Zimmer Biomet Holdings Inc (NYSE:ZBH) Presents a Compelling Case for Value Investors ↗

February 07, 2026

Via Chartmill

Zimmer Biomet Holdings Inc (NYSE:ZBH): A Durable Dividend Cornerstone for Income Investors ↗

February 03, 2026

Via Chartmill

Zimmer Biomet Holdings Inc (NYSE:ZBH) Screened as a 'Decent Value' Investment Opportunity ↗

January 13, 2026

Via Chartmill

Zimmer Biomet Holdings Inc. (NYSE:ZBH) Offers a Reliable Dividend Backed by Steady Fundamentals ↗

January 05, 2026

Via Chartmill

3 Reasons ZBH is Risky and 1 Stock to Buy Instead

February 02, 2026

Over the past six months, Zimmer Biomet’s shares (currently trading at $86.64) have posted a disappointing 6.2% loss, well below the S&P 500’s 9.6% gain. This might have investors contemplating their...

Via StockStory

Topics Stocks

3 Value Stocks with Open Questions

January 25, 2026

Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are...

Via StockStory

Q3 Rundown: Zimmer Biomet (NYSE:ZBH) Vs Other Surgical Equipment & Consumables - Diversified Stocks

January 20, 2026

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Zimmer Biomet (NYSE:ZBH) and...

Via StockStory

Topics Artificial Intelligence Economy

3 Cash-Producing Stocks with Open Questions

January 18, 2026

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.

Via StockStory

Topics Artificial Intelligence

1 Profitable Stock to Research Further and 2 Facing Challenges

January 15, 2026

Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.

Via StockStory

Solventum (SOLV): The 3M Spin-Off That Found Its Rhythm – A 2026 Deep-Dive Analysis

January 14, 2026

Date: January 14, 2026 Introduction Since its high-profile separation from industrial conglomerate 3M Company (NYSE: MMM) in April 2024, Solventum Corporation (NYSE: SOLV) has undergone a profound...

Via Finterra

Topics Artificial Intelligence World Trade

3 S&P 500 Stocks We Approach with Caution

January 08, 2026

The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth,...

Via StockStory

Topics Stocks

Top gainers and losers in the S&P500 index during Monday's after-hours session. ↗

December 29, 2025

Wondering what's happening in today's after-hours session with S&P500 stocks? Stay tuned for the latest updates on movers and shakers.

Via Chartmill

Zimmer Biomet Holdings Inc (NYSE:ZBH) Presents a Compelling Value Case for Disciplined Investors ↗

December 19, 2025

Zimmer Biomet (ZBH) presents a value investing case, trading at a significant discount to the market and its industry while maintaining solid profitability and financial health.

Via Chartmill

Zimmer Biomet Holdings Inc (NYSE:ZBH) Presents a Notable Case for Value Investors ↗

November 27, 2025

Zimmer Biomet (ZBH) presents a compelling value investment case with strong valuation metrics, solid earnings capability, and a stable balance sheet in the healthcare sector.

Via Chartmill

Zimmer Biomet, Cigna, Universal Health Services, Henry Schein, and Sotera Health Company Shares Skyrocket, What You Need To Know

November 21, 2025

A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated...

Via StockStory

Topics Economy Government

Great Rotation: Tech Exodus Fuels Dow's Record Run While Nasdaq Struggles

December 12, 2025

As of December 12, 2025, the financial markets are witnessing a significant "Great Rotation," a pronounced shift of capital from high-growth technology and Artificial Intelligence (AI) stocks to more...

Via MarketMinute

Topics Artificial Intelligence Bonds Economy

Bragar Eagel & Squire, P.C. Is Investigating Gauzy and Zimmer Biomet and Encourages Investors to Contact the Firm

November 20, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

Zimmer Biomet Holdings, Inc. (ZBH) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

November 13, 2025

From Law Offices of Howard G. Smith

Via Business Wire

Securities Fraud Investigation Into Zimmer Biomet Holdings, Inc. (ZBH) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm

November 13, 2025

From Glancy Prongay & Murray LLP

Via Business Wire

Securities Fraud Investigation Into Zimmer Biomet Holdings, Inc. (ZBH) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

November 12, 2025

From The Law Offices of Frank R. Cruz

Via Business Wire

2 S&P 500 Stocks Worth Your Attention and 1 We Turn Down

November 10, 2025

While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural...

Via StockStory

Topics Stocks

This Zimmer Biomet Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday ↗

November 06, 2025

Via Benzinga

Curious about which S&P500 stocks are generating unusual volume on Wednesday? Find out below. ↗

November 05, 2025

Curious about which S&P500 stocks are generating unusual volume on Wednesday? Find out below.

Via Chartmill

Exploring the top movers within the S&P500 index during today's session. ↗

November 05, 2025

Curious about the S&P500 stocks that are in motion on Wednesday? Join us as we explore the top movers within the S&P500 index during today's session.

Via Chartmill

Stocks Rebound, Eli Lilly Jumps To 14-Month Highs: What's Moving Markets Wednesday? ↗

November 05, 2025

Wall Street bounced back Wednesday after Tuesday's sharp selloff in AI-driven stocks, as investors bought the dip amid solid corporate earnings and growing signs that the Federal Reserve may be nearing...

Via Benzinga

Topics Economy

Zimmer Biomet Stock Falls As Weakness In Latin America And Certain EU Markets Impact Organic Growth Forecast ↗

November 05, 2025

Zimmer Biomet beats Q3 earnings estimates with strong U.S. sales, driven by new products, while reaffirming 2025 guidance and narrowing growth outlook.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.